Objectives This study was aimed at investigating the prevalence of obesity in drug-naive first-
episode (DNFE) patients with schizophrenia and its association with metabolic parameters …

Schizophrenia is associated with increased death rates and a reduced life span. Accidents
and suicide do not account for the vast majority of such deaths. Evidence suggests that …

Objective: Studies have reported that up to 60% of individuals with schizophrenia and 68%
of those with bipolar disorder are overweight/obese. This paper explores the health‐related …

Few studies have examined gender differences in the propensity to gain weight on
clozapine. Weight gain increases risk for many medical illnesses and is of particular concern …

Overweight and obesity are frequently reported to be a significant issue in schizophrenia
resulting in the inherent complications of these disorders. Body weight gain also commonly …

Objective: To determine the effect of Metformin in reducing Olanzapine induced weight gain
in people with Schizophrenia. Methodology: This randomized controlled trial was conducted …

The tendency of most of the second generation antipsychotics to induce weight gain to a
larger extent than that of traditional neuroleptics has renewed the interest in weight …

Sex differences in schizophrenia have been well recognized. However, sex differences in
obesity associated with antipsychotics have received little systematic study. This study was …

Second generation antipsychotics (SGAs), such as clozapine, olanzapine, risperidone and
quetiapine, are among the most effective therapies to stabilize symptoms schizophrenia (SZ) …

BACKGROUND: Antipsychotic medication and lifestyle factors are implicated in the high
rates of obesity and metabolic syndrome in schizophrenia. It was unclear whether …